October 23, 2026
Celltrion and Kaigene sign $580m licence deal for KG013
South Korean biopharmaceutical company Celltrion has acquired exclusive global development and commercialisation rights to Kaigene’s investigational monoclonal antibody, KG013, in a deal worth up to Won769bn ($580m).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







